Trials / Recruiting
RecruitingNCT05430009
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- VA Ann Arbor Healthcare System · Federal
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Liver SBRT | 24-45 Gy delivered in 3-5 fractions to 1-4 lesions. |
| DRUG | Pembrolizumab | 200 mg every 3 weeks or 400 mg every 6 weeks |
Timeline
- Start date
- 2022-06-17
- Primary completion
- 2025-12-15
- Completion
- 2026-06-15
- First posted
- 2022-06-24
- Last updated
- 2022-08-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05430009. Inclusion in this directory is not an endorsement.